会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Tricyclic mono-chromone-2-carboxylic acids
    • 三环单色酮-2-羧酸
    • US4159273A
    • 1979-06-26
    • US869654
    • 1978-01-16
    • Roger C. BrownRichard HazardJohn Mann
    • Roger C. BrownRichard HazardJohn Mann
    • C07D311/58C07D311/74C07D311/78C07D311/92C07D493/04C07D311/22A61K31/35
    • C07D493/04C07C45/513C07C45/54C07C45/62C07C45/63C07C45/64C07C45/67C07C45/71C07C45/75C07D311/58C07D311/74C07D311/78C07D311/92Y10S514/826
    • There are described compounds of formula I, ##STR1## in which R.sub.3 represents hydrogen, or alkyl C 1 to 6, R.sub.5 represents hydrogen, hydroxy, alkoxy C 1 to 6, alkanoyloxy C 2 to 6, alkenyloxy C 2 to 6, nitro, -NR.sub.1 R.sub.2, halogen, alkyl C 1 to 6, hydroxy-alkyl C 1 to 6, or hydroxy-alkoxy C 1 to 6,An adjacent pair of X, Y and Z form a --(CH.sub.2).sub.4 --, --CH.dbd.CH--CH.dbd.CH--or --O(CH.sub.2).sub.3 --chain, each of the chains optionally being substituted by one or two C 1 to 6 alkyl groups, and the remaining substituent X or Z represents alkenyl C2 to 6 optionally substituted by phenyl; halogen; or alkyl C 1 to 9 optionally substituted by one or more of the groups hydroxy, halogen, carbonyl oxygen, phenyl, or alkoxy C 1 to 6,Or, when an adjacent pair of X, Y and Z form a chain substituted by one or two C 1 to 6 alkyl groups, the remaining substituent X or Z may be hydrogen, andR.sub.1 and R.sub.2, which may be the same or different, are each hydrogen or alkyl C 1 to 6,And pharmaceutically acceptable derivatives thereof.Processes for making the compounds and pharmaceutical, e.g. anti-allergic, compositions containing the compounds are also described.
    • 描述了式I的化合物,其中R 3表示氢,或C 1至6的烷基,R 5表示氢,羟基,烷氧基C 1-6,烷酰氧基C 2-6,烯氧基C 2-6,硝基 ,-NR1R2,卤素,C1-6烷基,羟基 - 烷基C1至6,或羟基 - 烷氧基C1至6,X,Y和Z的相邻对形成 - (CH 2)4 - , - CH = CH-CH = CH-或-O(CH 2)3 - 链,每个链任选被一个或两个C 1-6烷基取代,其余取代基X或Z表示任选被苯基 ; 卤素; 或任选被一个或多个羟基,卤素,羰基氧,苯基或烷氧基C 1-6取代的烷基C 1至9,当X,Y和Z的相邻对形成被一个或多个 两个C 1-6烷基,剩余的取代基X或Z可以是氢,R 1和R 2可以相同或不同,分别为氢或C 1-6烷基,以及其药学上可接受的衍生物。
    • 2. 发明授权
    • Tricyclic mono-chromone-2-carboxylic acids
    • 三环单色酮-2-羧酸
    • US4238606A
    • 1980-12-09
    • US35739
    • 1979-05-03
    • Roger C. BrownRichard HazardJohn Mann
    • Roger C. BrownRichard HazardJohn Mann
    • C07D311/24C07C45/54C07C45/62C07C45/63C07C45/64C07C45/67C07C45/71C07C49/83C07C49/86C07D20060101C07D311/58C07D311/74C07D311/78C07D311/92C07D493/04C07D311/22
    • C07D493/04C07C45/54C07C45/62C07C45/63C07C45/64C07C45/67C07C45/673C07C45/71C07D311/58C07D311/74C07D311/78C07D311/92
    • There are described compounds of formula I, ##STR1## in which R.sub.3 represents hydrogen, or alkyl C 1 to 6,R.sub.S represents hydrogen, hydroxy, alkoxy C 1 to 6, alkanoyloxy C 2 to 6, alkenyloxy C 2 to 6, nitro, --NR.sub.1 R.sub.2, halogen, alkyl C 1 to 6, hydroxy-alkyl C 1 to 6, or hydroxy-alkoxy C 1 to 6,an adjacent pair of X, Y and Z form a --(CH.sub.2).sub.4 --, --CH.dbd.CH--CH.dbd.CH-- or --O(CH.sub.2).sub.3 -- chain, each of the chains optionally being substituted by one or two C 1 to 6 alkyl groups, and the remaining substituent X or Z represents alkenyl C 2 to 6 optionally substituted by phenyl; halogen; or alkyl C 1 to 9 optionally substituted by one or more of the groups hydroxy, halogen, carbonyl oxygen, phenyl, or alkoxy C 1 to 6,or, when an adjacent pair of X, Y and Z form a chain substituted by one or two C 1 to 6 alkyl groups, the remaining substituent X or Z may be hydrogen, andR.sub.1 and R.sub.2, which may be the same or different, are each hydrogen or alkyl C 1 to 6,and pharmaceutically acceptable derivatives thereof.Processes for making the compounds and pharmaceutical, e.g. anti-allergic, compositions containing the compounds are also described.
    • 描述了式I的化合物,其中R 3表示氢,或C 1至6的烷基,RS表示氢,羟基,烷氧基C 1-6,烷酰氧基C 2-6,烯氧基C 2-6,硝基 ,-NR1R2,卤素,C1-6烷基,羟基 - 烷基C1至6,或羟基 - 烷氧基C1至6,相邻的一对X,Y和Z形成 - (CH 2)4 - , - CH = CH-CH = CH-或-O(CH 2)3 - 链,每个链任选被一个或两个C 1-6烷基取代,其余的取代基X或Z表示任选被 苯基; 卤素; 或任选被一个或多个羟基,卤素,羰基氧,苯基或烷氧基C 1-6取代的C 1至9烷基,或者当相邻的一对X,Y和Z形成被一个或多个 两个C 1至6个烷基,其余的取代基X或Z可以是氢,R 1和R 2可以相同或不同,分别为氢或C 1-6烷基,及其药学上可接受的衍生物。 制备化合物和药物的方法,例如 还描述了抗过敏剂,含有这些化合物的组合物。
    • 3. 发明授权
    • 7-(2-aminoethyl) benzothiazolones
    • 7-(2-氨基乙基)苯并噻唑酮
    • US5648370A
    • 1997-07-15
    • US348154
    • 1994-11-28
    • Roger V. BonnertRoger C. BrownDavid R. CheshireFrancis InceJohn Dixon
    • Roger V. BonnertRoger C. BrownDavid R. CheshireFrancis InceJohn Dixon
    • C07C233/43C07D209/34C07D235/26C07D277/68C07D417/12A61K31/425
    • C07D277/68C07C233/43C07D209/34C07D235/26C07D417/12
    • There are disclosed compounds of formula I,Ar--CH.sub.2 CH.sub.2 --NH--CR.sup.1 R.sup.2 --X--Y Iin whichAr represents a group, ##STR1## X represents a C.sub.1-12 alkylene chain optionally interrupted or terminated by one or more groups selected from --S(O).sub.n --, --O--, --C(Z)--, CR.sup.6 R.sup.7, phenylmethyne, --NR.sup.8 --, --CONH--, --NHCO-- and --NHCONH--,Y represents an optionally substituted aryl or cycloalkyl group,Z represents O or S,R.sup.1, R.sup.2, R.sup.5 and R.sup.9 each independently represent hydrogen or alkyl C.sub.1-6,R.sup.3 and R.sup.4 represent hydrogen, or R.sup.3 and R.sup.4 together form a group --S--, --NR.sup.9 -- or --CH.sub.2 --,R.sup.6 and R.sup.7 independently represent hydrogen, alkyl C.sub.1-6, fluoro, cyano, or CF.sub.3, provided that at least one of R.sup.6 and R.sup.7 is other than hydrogen,R.sup.8 represents hydrogen or alkyl C.sub.1-6, or when X is interrupted or terminated by more than one --NR.sup.8 -- group may together with another R.sup.8 group form the chain --CH.sub.2 --CH.sub.2 --, andn represents 0, 1 or 2,and pharmaceutically acceptable derivatives thereof.Processes for their production and pharmaceutical compositions and methods of treatment involving their use are also described.
    • 公开了式I的化合物,Ar-CH2CH2-NH-CR1R2-X-Yinin,其中Ar表示一个基团,X表示C1-12亚烷基链,任选地被一个或多个选自-S( O)n - , - C(Z) - ,CR 6 R 7,苯基甲炔基,-NR 8 - , - CONH - , - NHCO-和-NHCONH-,Y表示任选取代的芳基或环烷基,Z表示O或 S,R 1,R 2,R 5和R 9各自独立地表示氢或烷基C 1-6,R 3和R 4表示氢,或者R 3和R 4一起形成基团-S - , - NR 9 - 或-CH 2 - ,R 6和R 7独立地表示 氢,烷基C 1-6,氟,氰基或CF 3,条件是R 6和R 7中的至少一个不是氢,R 8表示氢或C 1-6烷基,或者当X被多于一个-NR 8中断或终止时 - 基团可以与另一个R8基团一起形成链-CH2-CH2-,n代表0,1或2及其药学上可接受的衍生物。 还描述了其生产方法和药物组合物及其使用方法。
    • 7. 发明授权
    • 7-(2-aminoethyl) benzothiazolones
    • 7-(2-氨基乙基)苯并噻唑酮
    • US5763465A
    • 1998-06-09
    • US740622
    • 1996-10-31
    • Roger V. BonnertRoger C. BrownDavid R. CheshireFrancis InceJohn Dixon
    • Roger V. BonnertRoger C. BrownDavid R. CheshireFrancis InceJohn Dixon
    • C07C233/43C07D209/34C07D235/26C07D277/68C07D417/12A61K31/425A61K31/16C07C233/02C07D277/62
    • C07D277/68C07C233/43C07D209/34C07D235/26C07D417/12
    • There are disclosed compounds of formula I, Ar--CH.sub.2 CH.sub.2 --NH--CR.sup.1 R.sup.2 --X--Y I in which Ar represents a group, ##STR1## X represents a C.sub.1-12 alkylene chain optionally interrupted or terminated by one or more groups selected from --S(O).sub.n --, --O--, --C(Z)--, CR.sup.6 R.sup.7, phenylmethyne, --NR.sup.8 --, --CONH--, --NHCO-- and --NHCONH--, Y represents an optionally substituted aryl or cycloalkyl group, Z represents O or S, R.sup.1, R.sup.2, R.sup.5 and R.sup.9 each independently represent hydrogen or alkyl C.sub.1-6, R.sup.3 and R.sup.4 represent hydrogen, or R.sup.3 and R.sup.4 together form a group --S--, --NR.sup.9 -- or --CH.sub.2 --, R.sup.6 and R.sup.7 independently represent hydrogen, alkyl C.sub.1-6, fluoro, cyano, or CF.sub.3, provided that at least one of R.sup.6 and R.sup.7 is other than hydrogen, R.sup.8 represents hydrogen or alkyl C.sub.1-6, or when X is interrupted or terminated by more than one --NR.sup.8 -- group may together with another R.sup.8 group form the chain --CH.sub.2 --CH.sub.2 --, and n represents 0, 1 or 2, and pharmaceutically acceptable derivatives thereof. Processes for their production and pharmaceutical compositions and methods of treatment involving their use are also described.
    • 公开了式I,Ar-CH 2 CH 2 -NH-CR 1 R 2 I-XY I的化合物,其中Ar表示被一个或多个选自-S(O)n - , - O - , - C (Z) - ,CR6R7,苯基甲炔,-NR8-,-CONH-,-NHCO-和-NHCONH-,Y表示任选取代的芳基或环烷基,Z表示O或S,R1,R2,R5和R9各自独立地 代表氢或烷基C1-6,R3和R4代表氢,或R3和R4一起形成基团-S-,-NR9-或-CH2-,R6和R7独立地表示氢,烷基C1-6,氟,氰基, 或CF 3,条件是R 6和R 7中的至少一个不是氢,R 8表示氢或C 1-6烷基,或当X被多于一个-NR 8 - 基团中断或终止时,可以与另一个R8基团形成链 -CH 2 -CH 2 - ,n表示0,1或2,及其药学上可接受的衍生物。 还描述了其生产方法和药物组合物及其使用方法。
    • 8. 发明授权
    • 1,3,4-thiadiazoles
    • 1,3,4-噻二唑
    • US4927822A
    • 1990-05-22
    • US901048
    • 1986-08-27
    • Roger C. BrownJohn DixonDavid H. Robinson
    • Roger C. BrownJohn DixonDavid H. Robinson
    • A61K31/41A61K31/4245A61K31/433A61K31/44A61K31/4427A61K31/443A61K31/54A61K38/00A61P9/12A61P43/00C07D249/12C07D253/06C07D271/10C07D285/12C07D285/125C07D285/135C07D285/16C07D401/04C07D405/04C07D413/04C07D417/04C07K5/02C07K5/068C12N9/99
    • C07D253/06C07D271/10C07D285/12C07D285/135C07D285/16C07D417/04C07K5/0222C07K5/06086A61K38/00
    • There are described compounds of formula I, ##STR1## in which Y is S, O or NR.sub.9,n is 0 or 1,R.sub.9 is hydrogen or alkyl C 1 to 10,R.sub.3 is hydrogen, alkyl C 1 to 10, cycloalkyl C3 to 10, CF.sub.3, SR.sub.10, a 5 or 6 membered heterocyclic group containing one or more S, O or N atoms, NR.sub.4 R.sub.5, phenyl or phenylalkyl C7 to 12, the phenyl, phenylalkyl and heterocyclic groups optionally being fused to a further phenyl group, the heterocyclic group and any phenyl group optionally being substituted by alkyl C 1 to 6, halogen, alkoxy C 1 to 6, nitro, nitrile, CF.sub.3, SR.sub.6, NR.sub.7 R.sub.11 or hydroxy,R.sub.6, R.sub.7 and R.sub.11, which may be the same or different, are each hydrogen or alkyl C 1 to 10,R.sub.4 and R.sub.5, which may be the same or different, are each hydrogen, alkyl C 1 to 10 or phenyl,R.sub.10 is alkyl C 1 to 10,X.sub.1 is S or O, andA is a chain comprising from 2-16 atoms, which chain carries an O or S containing substitutent at a position 2-6 atoms away from the group C=X.sub.1,and pharmaceutically acceptable salts, esters and amides thereof, p1 there are also described method of making the compounds and pharmaceutical formulations, e.g. for the treatment of hypertension, containing them.
    • 描述了式I的化合物,其中Y是S,O或NR9,n是0或1,R9是氢或烷基C1至10,R3是氢,烷基C1至10,环烷基C3 至10,CF 3,SR 10,含有一个或多个S,O或N原子的5或6元杂环基,NR 4 R 5,苯基或苯基烷基C 7至12,任选地与另外的苯基稠合的苯基,苯基烷基和杂环基, 杂环基和任选被烷基C 1-6取代的任何苯基,卤素,烷氧基C 1至6,硝基,腈,CF 3,SR 6,NR 7 R 11或羟基,R 6,R 7和R 11可以相同或不同 各自为氢或烷基C 1至10,R 4和R 5可以相同或不同,各自为氢,烷基C 1至10或苯基,R 10为烷基C 1至10,X 1为S或O,以及 A是包含2-16个原子的链,该链在距离基团C = X1的2-6个原子的位置上携带含有O或S的取代基,以及药学上可接受的盐,酯和酰胺 除此之外,还描述了制备化合物和药物制剂的方法,例如, 用于治疗高血压,包含它们。
    • 9. 发明授权
    • Substituted theophylline compounds
    • 取代茶碱化合物
    • US4299832A
    • 1981-11-10
    • US89286
    • 1979-10-30
    • Roger C. BrownRodney A. BrownStephen E. O'Connor
    • Roger C. BrownRodney A. BrownStephen E. O'Connor
    • C07D473/08
    • C07D473/08
    • The substituted theophyllines of the formula: ##STR1## (wherein R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each represent alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl or phenylalkyl of 7 to 10 carbon atoms, each of which may be unsubstituted or substituted by one or more hydroxy groups, alkoxy or alkylthio groups of 1 to 4 carbon atoms, halogen atoms, cyano groups, nitro groups, carboxy groups, alkoxycarbonyl groups of 2 to 5 carbon atoms, amino groups, alkylamino groups of 1 to 4 carbon atoms or dialkylamino groups of 2 to 8 carbon atoms, or when the group is phenyl or phenylalkyl, by one or more alkyl groups of 1 to 4 carbon atoms;or R.sup.2 and R.sup.3 together represent a hydrocarbon chain of 3 to 6 carbon atoms optionally interrupted by a heteroatom;and n represents an integer of from 1 to 6)and the acid additional salts thereof, are novel compounds which are useful in the treatment of cardiac disorders. Processes for their preparation and pharmaceutical compositions containing them are also described.
    • 下式的取代茶碱:其中R 1,R 2和R 3可相同或不同,各自表示1至6个碳原子的烷基,3至7个碳原子的环烷基,苯基或苯基烷基 每个可以是未取代的或被一个或多个羟基,1-4个碳原子的烷氧基或烷硫基,卤原子,氰基,硝基,羧基,烷氧基羰基取代为2〜 具有1至4个碳原子的烷基氨基或2至8个碳原子的二烷基氨基,或当该基团为苯基或苯基烷基时,通过一个或多个含有1至4个碳原子的烷基;或R 2和 R3一起表示3〜6个碳原子的烃链,任选被杂原子中断; n表示1〜6的整数)及其酸的附加盐,可用于治疗心脏病。 还描述了其制备方法和含有它们的药物组合物。